Cancer Peptide Vaccination with UFT/LV Chemotherapy for Patients with Metastatic Colorectal Cancer
スポンサーリンク
概要
- 論文の詳細を見る
Recently, analyses of gene expression profiles of cancer and normal cells using cDNA microarray technologies have provided an effective approach for the identification of tumor-associated antigens. Two novel antigens, RNF43 and TOMM 34, were found to be up-regulated in more than 80％ of colorectal cancer tissues as compared to the corresponding noncancerous mucosa. We conducted a clinical trial of two novel peptide vaccine derived from RNF43 and TOMM34 in combination with UFT/LV for the treatment of recurrent colorectal cancer. Among 23 patients, 21 patients had completed the protocol. All patients were well tolerated with no severe toxicities. The median survival time was 24.4 months. Furthermore, we investigated the relationship between CTL response to both antigens and overall survival. The best long-term survival was observed in the group with CTL responses against both antigens, followed by the group showing CTL responses against only RNE43 or TOMM34. The patients with no response had the lowest survival. Further clinical trials are warranted.
- 日本外科系連合学会の論文
日本外科系連合学会 | 論文
- 大腸内視鏡検査後に横行結腸の大網穿通により皮下気腫・後腹膜気腫を発症した１例
- 食道神経鞘腫の１例
- 切除不能・再発大腸癌に対し，２次治療以降に行ったｍＦＯＬＦＯＸ６療法の治療成績
- Composix Mesh®を用いて腹腔鏡下に修復したMorgagni孔ヘルニアの１例
- 膀胱癌術前検査のＭＲＩ拡散強調画像で発見された直腸Ｓ状部癌の１例